tirzepatide and hashimoto's disease thyroid nodules: what the research actually shows about safety Tirzepatide as a Potential Disease-Modifying

Understanding your genetic predisposition to GLP-1 sensitivity can help your provider fine-tune your starting dose or protocol to minimize diarrhea risk from the beginning

Very common (10% of patients) Nausea peaks during titration, typically subsides within 48 weeks at a stable dose Vomiting, diarrhoea, constipation Abdominal pain or discomfort Reduced appetite (this is the therapeutic effect, not an adverse effect) Less common but serious stop and see a doctor Severe, persistent abdominal pain radiating to the back possible pancreatitis Right upper abdomen pain, fever, yellowing possible gallstones / gallbladder disease Persistent neck lump, hoarseness, difficulty swallowing evaluate thyroid Rapid heartbeat, severe dehydration from vomiting Hypoglycaemia when semaglutide is combined with insulin or sulfonylureas What the Indian data shows: a 2025 study of Indian patients found GI side effects are the leading cause of discontinuation, peaking during dose escalation

Mol Metab 30:72130

followup windows in pivotal trials commonly ranged from ~12 weeks to 72 weeks, with many key results at 2652 weeks

This interaction was disrupted by the ruthenium-based CO-releasing molecule, CORM3, but not by RuCl 3 as a control reagent (Fig

1989 Jan 26;337(6205):362-4